TLXTelix Pharmaceuticals Limited
$9.90-7.1% 1Y
$9.90
$6.4152 weeks$12.84
The business
How TLX's business earns
Telix Pharmaceuticals Limited earns 3.5% on the capital it employs against an estimated 9.0% cost of capital.
3.5%
Return on invested capital · cost of capital 9.0% · 5.5 points below the estimated cost of capital
- Operating margin
- 3.7%
Operating margin · Biotechnology median −61% · fiscal year to Dec 31, 2025
- Cash conversion
- −0.73×
Cash conversion · 0.56× a year ago · operating cash flow divided by operating profit after tax
- Share count, year on year
- −2.1%
Share count, year on year · fewer shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2023 | 3.3% |
| FY2024 | 11% |
| FY2025 | 3.7% |
Details›
- Gross marginfiscal year to Dec 31, 2025
- 53%
- Operating marginfiscal year to Dec 31, 2025
- 3.7%
- Net marginfiscal year to Dec 31, 2025
- −0.89%
- Free cash flow margin
- −5.3%
- R&D as % of revenue
- 21%
- Revenue, trailing twelve months
- $804M
- Free cash flow, trailing twelve months
- −$43M
- Net income, trailing twelve months
- −$7.1M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 3.5%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry